VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN Trial.

[1]  C. Jiang,et al.  Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease , 2007, Gene Therapy.

[2]  D. Stewart,et al.  Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment , 2006, Gene Therapy.

[3]  Y. Huang,et al.  An engineered VEGF‐activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced‐age mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[5]  D. Geddes,et al.  The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia. , 2005, European heart journal.

[6]  F. Sellke,et al.  Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. , 2005, The American journal of cardiology.

[7]  H. Bøtker,et al.  Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. , 2005, Journal of the American College of Cardiology.

[8]  T. Henry,et al.  Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. , 2005, Journal of interventional cardiology.

[9]  F. Sellke,et al.  Nitric oxide and the angiogenic response: can we improve the results of therapeutic angiogenesis? , 2005, Expert opinion on investigational drugs.

[10]  M. Kutryk,et al.  Therapeutic neovascularization for ischemic heart disease. , 2004, The Canadian journal of cardiology.

[11]  M. Kutryk,et al.  Clinician Guide to Angiogenesis , 2003, Circulation.

[12]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[13]  R. Hendel,et al.  Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia , 2002, Circulation.

[14]  C. Grines,et al.  Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris , 2002, Circulation.

[15]  T. Henry,et al.  Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.

[16]  D. Latchman,et al.  In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo , 2001, Gene Therapy.

[17]  M. Dake,et al.  Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. , 2001, Journal of the American College of Cardiology.

[18]  C. Yoshizawa,et al.  Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease , 2001, Journal of clinical pharmacology.

[19]  J. Pearlman,et al.  Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. , 2000, The Annals of thoracic surgery.

[20]  R O Bonow,et al.  Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. , 2000, Circulation.

[21]  P. Kligfield,et al.  Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. , 1999, Annals of surgery.

[22]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[23]  N. Ferrara.  Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[24]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[25]  M. Leon,et al.  Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. , 1998, Circulation.

[26]  D. Dadhania,et al.  Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. , 1997, Cardiovascular research.

[27]  J. Wolff.  Naked DNA transport and expression in mammalian cells , 1997, Neuromuscular Disorders.

[28]  M. Majesky.  A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA. , 1996, Circulation.

[29]  A. Popel,et al.  retention model of myocardial deposition and Intracoronary administration of FGF-2: a , 2005 .